TMP1

TMP1 is an orally active dual inhibitor targeting M pro (IC50= 312.5 nM) and TMPRSS2 (IC50= 1.28 μM, KD= 10.10 μM) . It shows broad-spectrum protective effects in vitro against various SARS-CoV-2 variants. In vivo, TMP1 provides cross-protection against highly pathogenic coronaviruses, including SARS-CoV-1, SARS-CoV-2, and MERS-CoV, and effectively blocks the transmission of SARS-CoV-2. Additionally, TMP1 can inhibit the infection of SARS-CoV-2 escape mutants resistant to Nivolumab. TMP1 is useful in coronavirus research.